Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma - 16/05/19
![](/templates/common/images/mail.png)
Dr Ross is currently affiliated with Upstate Medical University's Department of Pathology and Laboratory Medicine. Dr Russell is currently affiliated with Janssen Pharmaceuticals. |
|
Dr Boussemart, Ms Johnson, and Dr Schrock contributed to this work equally. |
|
Funding sources: None. |
|
Conflicts of interest: Ms Johnson, Dr Schrock, Dr Frampton, Mr Fabrizio, Mr Chalmers, Dr Ross, Dr Stephens, Dr Miller, and Dr Ali were employed by and held equity interest in Foundation Medicine Inc at the time this study was performed. Foundation Medicine Inc is now a wholly owned subsidiary of Roche. Dr Lotem is an employee of TEVA Pharmaceuticals. Dr Boussemart, Dr Pal, Dr Gibney, Dr Chmielowski, and Dr Russell have no conflicts of interest to disclose. |
|
Reprints not available from the authors. |
Vol 80 - N° 6
P. 1780-1782 - juin 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?